1. Background {#sec1}
=============

Lung cancer is the leading cause of cancer-related death worldwide \[[@r1]\]. Its positive diagnosis is based on microscopic features and faced a recent change due to the 2015 World Health Organization Classification's \[[@r1], [@r2]\]. For the first time, this classification introduced molecular pathways and targets especially for adenocarcinomas. In fact, this histologic subtype has become the most frequent non-small-cell lung carcinoma. This classification pointed out the necessity of  not only assessing the accurate microscopic diagnosis but also the importance of molecular diagnosis of the most relevant targets. Lung cancer is mainly characterized by its spatial and temporal heterogeneity \[[@r3], [@r4]\]. Spatial heterogeneity consists in the presence in the same tumor of different molecular drivers. This fact compels to multiply samples in order to assess all the potential relevant pathways involved. On the other hand, temporal heterogeneity consists in the difference of activated pathways between the initial tumour and the metastases or the recurrences. This fact enhances the necessity of sampling the metastases or recurrences even if the initial tumoral profile was assessed. This heterogeneity provides also an explanation to the phenomenon of resistance, which is observed within 3 to 6 months after the onset of anti-EGFR treatments. This resistance is explained by the activation of secondary pathways that were activated at the onset but concerned a low number of tumour cells. The morphological and molecular tests are performed in 80% of the cases on small samples and molecular testing is impossible in 30% of the patients. This may be due to the unavailability of the specimen, the inaccessibility of the tumoral site or the presence of contraindications to biopsy \[[@r3]\]. This fact made scientists and researchers look for other surrogates to tissue that can be safer and sufficient to establish the molecular profile. In this context, the liquid biopsy was discovered. It consists in the assessment of molecular profile on circulating tumor cells, circulating tumoral DNA, circulating tumoral RNA, exosomes or secretomes \[[@r5]\]. Many studies were published concerning the assessment of these elements with varying techniques of identification. In 2014, the liquid biopsy was introduced in the management scheme of patient candidates for the third generation anti-EGFR in order to assess the presence of the T790M mutation \[[@r6], [@r7]\]. Besides, in 2016, the first technique of sequencing, the cobas EFGR mutation test, obtained the Food and Drug Administration approval \[[@r8], [@r9]\]. Even if this technique was approved, there are still many publications dealing with different techniques that may seem less expensive or easier to perform in a Pathology lab. Recently, many authors reported the efficiency of tests performed on free circulating DNA (cfDNA) in comparison with those performed on circulating tumour cells (CTC) \[[@r10]\]. We aimed to highlight the diagnostic value of liquid biopsy in assessing the molecular profile of non small cell carcinomas in comparison with tissue biopsy and we focused on the mutations of the Epidermal Growth Factor Receptor gene (EGFR). Other genes were assessed in only 4 included studies.

2. Methods {#sec2}
==========

2.1. Data Source and Search {#sec2.1}
---------------------------

We conducted this meta-analysis under the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@r11]\]. To retrieve all eligible articles, PubMed and Embase databases and Cochrane Library were comprehensively searched up to 01 June 2017 with limitation to French and English language. The search medical subject heading (MeSH) terms employed for literature retrieval included: lung cancer or lung neoplasm, cell free DNA or cfDNA or circulating DNA and diagnosis or sensitivity or specificity or accuracy. The reference list of eligible articles was also independently searched to obtain other valuable sources.

2.2. Study Selection Criteria {#sec2.2}
-----------------------------

To be qualified for inclusion in this meta-analysis, articles must comply with all the following criteria: articles evaluated the diagnosis value of cfDNA in plasma/serum or blood for lung cancer, the diagnosis of lung cancer was confirmed by the gold standard test which is the biopsy and articles provided sufficient data (true negative (TN), true positive (TP), false negative (FN) and false positive (FP)). The major exclusion criteria were as follows: studies with duplicate data reported in other studies and reviews, technical reports, case reports, comments or letters with invalid data.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

One investigator independently reviewed all the articles and extracted data from the selected articles: first authors' name, publication year, characteristics of participants (ethnicity, mean/median, age, source of control, number of cases and controls, sample types), assay methods, assay indicators, sensitivity, specificity and quality assessment information. In addition, based on the revised quality assessment of diagnosis, accuracy studies-2 (QUADAS-2) criteria, the included articles were evaluated as at high risk (H) or low risk (L) independently by four key domains: patient selection, index test, reference standard and flow and timing \[[@r12]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

We used the Meta-Disc software 5.1.32 to conduct this meta-analysis. The pooled sensitivity (SEN) (TP/TP+FN), specificity (SPE) (TN/TN+FP), negative likelihood ratio (NLR), positive likelihood ratios (PLR) and diagnostic odds ratio (DOR) with the 95% confidence intervals were calculated. At the same time, we constructed the summary receiver operator characteristic (SROC) curve and calculated the area under the SROC curve based on the SEN and SPE of each study.

### 2.4.1. Threshold Effect {#sec2.4.1}

A threshold effect was assessed using the Moses model with calculation of the Spearman correlation coefficient.

### 2.4.2. Heterogeneity {#sec2.4.2}

Q test and I^2^ statistics were carried out to explore the heterogeneity among studies. P value \<0.1 for q test or I^2^ value \>50% represented substantial between study heterogeneity. Besides, based on the characteristics of the included articles, meta-regressions were performed to explore the sources of heterogeneity if necessary.

### 2.4.3. Sensitivity Analysis {#sec2.4.3}

In case of absence of covariates, according to the meta-regression analysis, we performed a sensitivity analysis using the same software. This analysis is performed through a visual inspection of forest plots. Studies causing bias are those that show large deviations from the line corresponding to the pooled accuracy estimation mentioned in the forest plot of specificity. These studies were excluded and considered as possible sources of heterogeneity. The purpose of sensitivity analysis is to stipulate hypothesis about the sources of heterogeneity when metaregression shows no covariates.

3. RESULTS {#sec3}
==========

3.1. Search Results {#sec3.1}
-------------------

Our database research retrieved 839 records. After reviewing the title and abstracts, 729 records were excluded due to language limit, unrelated studies. By reviewing full-text articles, we excluded further 65 records, leaving 43 eligible articles and 2 international congress abstracts. From these articles, 16 records were excluded due to insufficient data (3 articles and 1 congress abstract), no gold standard (8 articles) and duplicate publications (4 articles). In the study reported by Li and colleagues, EGFR mutation was detected in both plasma and serum and the data of plasma and serum were analyzed as two independent studies \[[@r13]\]. Xu and coworkers described 3 different techniques for the specific analysis of the Exon19 deletion and the L858R mutation of the EGFR gene. So that, the different data were considered as 6 independent studies \[[@r14]\]. After independent review, 39 eligible studies were included in this meta-analysis. The  [Fig. (**[1](#F1){ref-type="fig"}**)](#F1){ref-type="fig"} illustrates the flow-chart of the literature retrieval.

All the studies fulfilled the major QUADAS-2 categories with a global low risk of bias and low concerns concerning applicability. The quality assessment of the different studies included is represented in Table **[1](#T1){ref-type="table"}**.

A total of 4,782 participants were included in the analysis. The majority of the patients presented a late stage lung cancer. All the studies dealt with the sequencing of the EGFR gene in association to the sequencing of TP53, NF1, KRAS, MET in 1 study \[[@r15]\], to BRAF in one study \[[@r16]\], to KRAS in 1 study \[[@r17]\] and 1 study dealt with the screening of the ALK gene \[[@r18]\]. The techniques of sequencing in the liquid biopsy and in the tissue were similar in 20 studies. In the other studies they were different. The molecular diagnosis was performed on liquid biopsy and tissue at the same time in 17 studies and was not specified in 10 studies. Many techniques of sequencing were used in liquid biopsy consisting in PCR-based-sequencing techniques and non PCR-based-sequencing techniques. PCR-based-sequencing techniques consisted in digital PCR (dPCR) \[[@r19]\], amplification refractory mutation system (ARMS) \[[@r17]\], CastPCR \[[@r16]\], peptide-nuclei-acid mediated PCR (PNA-PCR) \[[@r20]\], mutant-enriched PCR (ME-PCR) \[[@r21]\], High Resolution Melting (HRM) \[[@r22]\], mutant enriched-liquidchip PCR technique \[[@r14]\], PNA-LNA-PCR technique \[[@r23]\]. Non PCR-based tecniques consisted in next-generation sequencing (NGS) \[[@r18]\], Cobas EGFR mutation test \[[@r24]\], Therascreen \[[@r25]\] and denaturing high perforance liquid chromatography (DHPLC) technique \[[@r26]\]. The technique that was the most frequently used in this analysis was the scorpion ARMS technique. The NGS techniques were reported in only 5 studies. The Table **[2](#T2){ref-type="table"}** summarizes the main characteristics of the included articles.

3.2. Diagnostic Accuracy of the Liquid Biopsy {#sec3.2}
---------------------------------------------

The overall pooled SEN and SPE were 0.63 (95% CI, 0.61-0.65) and 0.92 (95% CI, 0.91-0.93) respectively (Figs. **2** and **3**). Our results showed that PLR was 8.123 (95% CI, 5.13-12.84), NLR was 0.456 (95% CI, 0.383-0.543) and DOR was 20.50 (95% CI, 12.61-33.30) (Fig. **[4](#F4){ref-type="fig"}**). Between-study heterogeneity was significant in the SEN, SPE and the DOR (I-square estimated to respectively 84.9%, 89.1% and 74.9%). We did not find any evidence of threshold effect (Spearman correlation coefficient: 0.029 and p=0.861). [Fig. (**[5](#F5){ref-type="fig"}**)](#F5){ref-type="fig"} shows the corresponding SROC curve with AUC of 0,82 indicating that the liquid biopsy is capable of identifying wild type samples from mutated ones with a relatively high accuracy.

3.3. Subgroup Analysis {#sec3.3}
----------------------

Sub-group analyses based on the use of the NGS technique, the use of scorpion ARMS technique, the use of DHPLC technique, the use of the same technique in the liquid biopsy and tissue and the analysis of specific mutations of the EGFR gene were also conducted. The NGS tehniques seem to have the highest sensitivity of 0.75 and the highest specificity was recorded in the group of the ARMS Scorpion technique. Even when we analyzed the group of studies using the same techniques in the tissue and the liquid

biopsy, we noticed a heterogeneity between the different studies. The studies screening the deletion in the exon19 and those reporting mutations of the different exons of the EGFR gene presented quite similar sensitivities and specificities with heterogeneity in all cases. Table **[3](#T3){ref-type="table"}** illustrates the different results.

3.4. Heterogeneity and Meta-Regression Analysis {#sec3.4}
-----------------------------------------------

The meta-regressions were also performed to further explore potential sources of heterogeneity (Table **[4](#T4){ref-type="table"}**). Our meta-regression analysis characteristics included 'ethnicity (Asian or not)', 'the technique (Next generation sequencing

or not)', 'tissue/plasma (same technique use in the tissue and plasma or not)', 'plasma/serum (studies performed on serum or not). We didn't include the smoking status as a possible covariate because of its subjective estimation by the patients. The meta-regression results suggested that no covariates might be responsible for this heterogeneity.

Sensitivity analysis: A sensitivity analysis was performed because of the presence of heterogeneity with no covariates highlighted by the meta-regression. We focused on the specificity forest plot because liquid biopsy is considered as a diagnostic test and mustn't induce the treatment of patients with no mutations. The sensitivity analysis excluded the studies of Que D, *et al*, Santos, *et al*, Douillard, *et al*, Huang, *et al*, Wang, *et al*, Weber, *et al*, Zhu, *et al*, Mack *et al*, Kuang *et al*, Sriram, *et al*, Xu, *et al.* and Sequist, *et al.* \[[@r30], [@r32], [@r34], [@r36], [@r38], [@r39], [@r40], [@r17], [@r36], [@r44], [@r14], [@r25]\]. The overall pooled SEN and SPE were 0.61 (95%CI, 0.58-0.64) and 0.95 (95%CI, 0.94-0.96) respectively (Figs. **2a** and **2b**). Our results showed that PLR was 9.51 (95%CI, 6.66-13.58), NLR was 0.45 (95%CI, 0.37-0.56) and DOR was 24.58 (95%CI, 15.23-39) (Figs. **3a**, **3b** and **4**). We noticed no heterogeneity between studies in the SPE, PLR and the DOR (I-square estimated to respectively 42%, 33% and 43.9%). The area under curve was estimated to 0.93. We did not find any evidence of threshold effect (p=0.159).

4. Discussion {#sec4}
=============

This meta-analysis highlighted the efficacy of liquid biopsy in determining the EGFR gene mutation status in non-small cell carcinoma. According to the suggested guidelines for interpretation of AUC, ctDNA had high accuracy (0.9\<AUC\<1) for detection of EGFR mutation status in NSCLC. The value of DOR ranges from 0 to infinity with higher values indicating better discriminatory test performance. Our results showed a high diagnostic performance with a DOR of 20.5 even without sensitivity analysis. The likelihood ratios provided information about the likelihood that a patient with a positive or negative result has EGFR mutation or not. In our study, the PLR of 8 and the NLR of 0.45 were quite high. The meta-regression proved that the nature of the liquid used (plasma or serum), the ethnicity, the similarity of the techniques used in the tissue and the liquid biopsy are not the potential sources of the heterogeneity observed. Few meta-analyses have been reported about the diagnostic value of liquid biopsy and they were published in late 2014. They described also an important heterogeneity between the different techniques. Qiu *et al.* investigated the effect of the detection methods, TNM stages, collection time and format of blood sample and treatment of tumor tissues as potential confounding factors without proving significant results \[[@r27]\]. In this meta-analysis, the majority of the studies were about late-staged carcinomas. Our sub-group analysis revealed a better sensitivity of next generation sequencing techniques with a better specificity of ARMS technique. Besides, even the stratified analysis of individual mutation, when applicable, showed relatively the same SEN and SPE with a significant heterogeneity between studies. Our sub-group analysis showed a heterogeneity even if studies were grouped based on the technique, the use of plasma or serum or the punctual mutation of the EGFR gene. The sensitivity analysis allowed achieving homogeneity by excluding 12 studies. The final group was characterized by the Asian ethnicity and the use of PCR-based techniques as diagnostic tests. It was quite surprising to exclude the study of Sequist *et al.* \[[@r25]\] which was based on NGS techniques. In their meta-analysis, Li and coworkers studied the importance of the country, the random or consecutive patient selection and test method and reported that test method was the unique contributing factor with p=0.00354 \[[@r28]\]. This meta-analysis included only 13 studies and the authors didn't perform a subgroup analysis.

We would like to discuss the potential limitations of this work. The fact that we didn't assess confounding factors highlights the multiplicity of these factors including the technical steps that are not discussed in the different studies, the percentage of tumor cells, the histologic subtype of the tumours, the collection time of blood sample, the detailed chemotherapy regimens that may be different sources of bias. Besides, most studies included tissue samples formalin-fixed paraffin-embedded which lead to significant DNA degradation and increase detection bias. This fact enhances further studies to investigate these issues.

Conclusion
==========

This meta-analysis suggested that detection of molecular mutations by cfDNA is of adequate diagnostic accuracy in association with tissues. The high specificity and the moderate sensitivity highlight the value of liquid biopsy as a screening test.

Sources of funding
==================

The authors report no external funding

Consent for Publication
=======================

Not applicable.

Declared none.

conflict of interest
====================

The authors declare no conflict of interest, financial or otherwise.
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![**a**) Forrest plot of sensitivity of all studies, **b**) Forrest plot of sensitivity after sensitivity analysis.](CRMR-14-48_F2){#F2}

![**a**) forrest plot of specificity of all studies, **b**) forrest plot of specificity after sensitivity analysis.](CRMR-14-48_F3){#F3}

![**a**) Forrest plot of likelihood ratios for positive test results of all studies, **b**) Forrest plot of likelihood ratios for positive test results after sensitivity analysis, **c**) forrest plot of likelihood ratios for negative test results of all studies, **d**) forrest plot of likelihood ratios for negative test results after sensitivity analysis.](CRMR-14-48_F4){#F4}

![**A**) The summary operative receiver characteristic curve indicating the area under curve of all studies, **B**) Forrest plot of dOR after sensitivity analysis.](CRMR-14-48_F5){#F5}

###### 

The quality assessment of the different studies included.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Studiess**                      **Risk of Bias**   **Applicability Concerns**                                                                                                   
  --------------------------------- ------------------ ---------------------------- --------------------- ----------------------- ---------------- ------------------------ --- --- ---
  Kimura *et al.* 2007 \[[@r29]\]   2007               42                           L                     L                       L                L                        L   L   L

  Bai *et al.* \[[@r26]\]           2009               230                          L                     L                       L                L                        L   L   L

  Que *et al*. \[[@r30]\]           2016               121                          L                     L                       L                L                        L   L   L

  Cui *et al*. \[[@r18]\]           2017               39                           L                     L                       L                L                        L   L   L

  Rachiglio\                        2016               44                           L                     L                       L                L                        L   L   L
  *et al.* \[[@r31]\]                                                                                                                                                               

  Santos\                           2016               63                           L                     L                       L                L                        L   L   L
  *et al.* \[[@r32]\]                                                                                                                                                               

  Goto *et al.*\                    2012               86                           L                     L                       H                L                        L   L   L
  \[[@r33]\]                                                                                                                                                                        

  Douillard \[[@r34]\]              2013               652                          L                     L                       H                L                        L   L   L

  He *et al.* \[[@r35]\]            2016               120                          L                     L                       H                L                        L   L   L

  Yang *et al.*\                    2017               107                          L                     L                       H                L                        L   L   L
  \[[@r16]\]                                                                                                                                                                        

  Huang *et al.* \[[@r36]\]         2012               822                          L                     L                       L                L                        L   L   L

  Liu *et al.* \[[@r10]\]           2013               86                           L                     L                       L                L                        L   L   L

  Kim *et al.*\                     2013               40                           L                     L                       L                L                        L   L   L
  \[[@r37]\]                                                                                                                                                                        

  Zhao *et al.* \[[@r21]\]          2012               111                          L                     L                       L                L                        L   L   L

  Wang *et al.* \[[@r38]\]          2014               134                          L                     L                       L                L                        L   L   L

  Jing *et al.* \[[@r22]\]          2014               120                          L                     L                       L                L                        L   L   L

  Weber *et al.* \[[@r39]\]         2014               196                          L                     L                       L                L                        L   L   L

  Zhang *et al.* \[[@r19]\]         2016               215                          L                     L                       L                L                        L   L   L

  Zhu *et al.* \[[@r40]\]           2015               172                          L                     L                       L                L                        L   L   L

  Mack *et al.* \[[@r17]\]          2009               14                           L                     L                       L                L                        L   L   L

  Kuang *et al.* \[[@r41]\]         2009               43                           L                     L                       L                L                        L   L   H

  He *et al.* \[[@r42]\]            2009               18                           L                     L                       L                L                        L   L   L

  Brevet *et al.* \[[@r29]\]        2011               31                           L                     L                       L                L                        L   L   L

  Jiang *et al.* \[[@r43]\]         2011               58                           L                     L                       H                L                        L   L   L

  Sriram *et al.* \[[@r44]\]        2011               64                           L                     L                       L                L                        L   L   L

  Xu *et al.* \[[@r14]\]            2012               34                           L                     L                       L                L                        L   L   L

  Xu *et al.* \[[@r14]\]            2012               34                           L                     L                       L                L                        L   L   L

  Xu *et al.* \[[@r14]\]            2012               34                           L                     L                       L                L                        L   L   L

  Xu *et al.* \[[@r14]\]            2012               34                           L                     L                       L                L                        L   L   L

  Xu *et al.* \[[@r14]\]            2012               34                           L                     L                       L                L                        L   L   L

  Xu *et al.* \[[@r14]\]            2012               34                           L                     L                       L                L                        L   L   L

  **Studiess**                      **Risk of Bias**   **Applicability Concerns**                                                                                                   

  **Patient Selection**             **Index Test**     **Reference Standard**       **Flow and Timing**   **Patient Selection**   **Index Test**   **Reference Standard**           

  Kim *et al.* \[[@r20]\]           2013               57                           L                     L                       L                L                        L   L   L

  Sequist *et al.* \[[@r25]\]       2015               227                          L                     L                       L                L                        L   L   L

  Wu \[[@r45]\]                     2015               24                           L                     L                       L                L                        L   L   L

  Mok \[[@r24]\]                    2015               238                          L                     L                       L                L                        L   L   L

  Li \[[@r13]\]                     2014               141                          L                     L                       H                L                        L   L   L

  Li \[[@r13]\]                     2014               108                          L                     L                       L                L                        L   L   L

  HE \[[@r35]\]                     2017               120                          L                     L                       L                L                        L   L   L

  Yung *et al.*\                    2009               35                           L                     L                       L                L                        L   L   L
  \[[@r29]\]                                                                                                                                                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

The major characteristics of the different studies included.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**\                 **TP**   **FP**   **FN**   **TN**   **Test**   **Genes**   **Ethnicity**                               **Test of Biopsy**             **Time Point of Biopsy and Liquid Biopsy**   **Stage**                                                        **Plasma/**\                                                **CR**                          
  **Year**\                                                                                                                                                                                                                                                                      **Serum**                                                                                   
  **Number**                                                                                                                                                                                                                                                                                                                                                                 
  -------------------------- -------- -------- -------- -------- ---------- ----------- ------------------------------------------- ------------------------------ -------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------- ---------------------- -------- -----
  Yung\                      2009     35       11       0        1          23          Microfluidics digital PCR                   Ex 19, L858R                   Asian                                        Direct sequencing                                                No mention                                                  No mention             plasma   97%
  *et al.* \[[@r29]\]                                                                                                                                                                                                                                                                                                                                                        

  Kimura\                    2007     42       6        1        2          33          ARMS                                        Ex 18, 19, 21                  Asian                                        Direct sequencing                                                BT liquid biopsy, not at the same time                      III or IV              serum    92%
  *et al.* 2007 \[[@r29]\]                                                                                                                                                                                                                                                                                                                                                   

  Bai\                       2009     230      63       16       14         137         DHPLC                                       Ex19, 21                       Asian                                        DHPLC                                                            No mention                                                  IIIb ou IV             plasma   87%
  *et al.* \[[@r26]\]                                                                                                                                                                                                                                                                                                                                                        

  Que\                       2016     121      34       10       10         67          DHPLC                                       Ex19, 21                       Asian                                        ARMS                                                             BT the same time                                            I-IIIa:17\             plasma   83%
  *et al*. \[[@r30]\]                                                                                                                                                                                                                                                                                                                        IIIb-IV:104.                    

  Cui\                       2017     39       13       0        11         15          NGS                                         ALK                            Asian                                        NGS                                                              Not at the same time                                        I-IIIa:7\              plasma   72%
  *et al*. \[[@r18]\]                                                                                                                                                                                                                                                                                                                        IIIb-IV:32                      

  Rachiglio *et al.*\        2016     44       17       2        5          20          NGS                                         EGFR                           European                                     NGS                                                              Not at the same time                                        IV                     Plasma   84%
  \[[@r31]\]                                                                                                                                                                                                                                                                                                                                                                 

  Santos\                    2016     63       33       10       15         5           NGS                                         EGFR, TP53, NF1, KRAS, MET     European                                     Not mentionned                                                   Not specified                                               Not specified          plasma   60%
  *et al.* \[[@r32]\]                                                                                                                                                                                                                                                                                                                                                        

  Goto\                      2012     86       22       0        29         35          Scorpion ARMS                               EGFR                           Asian                                        ARMS                                                             Pre-TT both                                                 Not specified          serum    66%
  *et al.* \[[@r33]\]                                                                                                                                                                                                                                                                                                                                                        

  Douillard \[[@r34]\]       2013     652      69       1        36         546         Scorpion ARMS (ex19 del, L858R, T790M)      EGFR                           European                                     Scorpion ARMS                                                    Both BT.                                                    Stage IIIa, b, IV      plasma   94%

  He\                        2016     120      80       0        26         14          Targeted (ddPCR) (Ex19 del, L858R, T790M)   EGFR                           Asian                                                                                                                                                                                                     78%
  *et al.* \[[@r35]\]                                                                                                                                                                                                                                                                                                                                                        

  **Study**\                 **TP**   **FP**   **FN**   **TN**   **Test**   **Genes**   **Ethnicity**                               **Test of Biopsy**             **Time Point of Biopsy and Liquid Biopsy**   **Stage**                                                        **Plasma/**\                                                **CR**                          
  **Year**\                                                                                                                                                                                                                                                                      **Serum**                                                                                   
  **Number**                                                                                                                                                                                                                                                                                                                                                                 

  Yang *et al.* \[[@r16]\]   2017     107      31       3        24         49          Cast PCR                                    EGFR, BRAF                     Asian                                        Not mentionned                                                   Not the same time                                           I-III:42\              plasma   74%
                                                                                                                                                                                                                                                                                                                                             IV:65                           

  Huang\                     2012     822      188      81       108        445         DHPLC                                       EGFR                           Asian                                        DHPLC                                                            THE SAME TIME                                               IIIb, IV: 744\         plasma   77%
  *et al.* \[[@r36]\]                                                                                                                                                                                                                                                                                                                        I-IIIa: 78                      

  Liu *et al.* \[[@r10]\]    2013     86       27       0        13         46          Scorpion ARMS                               EGFR                           Asian                                        ARMS                                                             No mention                                                  III ET IV              plasma   85%

  Kim\                       2013     40       6        0        29         5 exclus    PNA-mediated real-time PCR                  EX19 del, L858R                Asian                                        Direct sequencing                                                Not the same time                                           advanced               plasma   87%
  *et al.* \[[@r37]\]                                                                                                                                                                                                                                                                                                                                                        

  Zhao\                      2012     111      16       3        29         63          ME-PCR(19 del, L858 R)                      EGFR                           Asian                                        ME-PCR                                                           Same time BT                                                Not mentionned         plasma   71%
  *et al.* \[[@r21]\]                                                                                                                                                                                                                                                                                                                                                        

  Wang\                      2014     134      15       0        53         64          (ARMS SCORPION)                             EGFR\                          Asian                                        ARMS                                                             After TT                                                    115 IV, 19 IIIb        plasma   59%
  *et al.* \[[@r38]\]                                                                                                               VP: 15, FP: 2, VN: 4, FN: 53                                                                                                                                                                                                             

  Jing *et al.* \[[@r22]\]   2014     120      29       2        16         73          HRM + direct sequencing                     EGFR                           Asian                                        HRM + direct sequencing                                          During surgery for liquid biopsy. Not at the same moment,   I-II: 38\              plasma   85%
                                                                                                                                                                                                                                                                                                                                             III-IV:82                       

  Weber\                     2014     196      17       6        11         162         NGS (cobas)                                 EGFR                           European                                     cobas                                                            BT liquid biopsy, not at the same time                      I, II:2\               plasma   91%
  *et al.* \[[@r39]\]                                                                                                                                                                                                                                                                                                                        III, IV: 197                    

  Zhang\                     2016     215      57       4        36         118         ddPCR                                       Ex19 del, L858R                Asian                                        ARMS                                                             The same, AT                                                IIIb:36\               plasma   81%
  *et al.* \[[@r19]\]                                                                                                                                                                                                                                                                                                                        IV:179                          

  Zhu *et al.* \[[@r40]\]    2015     172      30       4        7          131         Targeted (ddPCR)                            Ex19 del, L858R                Asian                                        ARMS                                                             No mention                                                  Not mention            plasma   93%

  Mack\                      2009     14       4        4        2          4           (scorpion ARMS)                             EGFR, KRAS                     American                                     Nested PCR assay                                                 BT liquid biopsy not mentionned for tissue                  IIIb et IV             plasma   57%
  *et al.* \[[@r17]\]                                                                                                                                                                                                                                                                                                                                                        

  Kuang\                     2009     43       21       9        2          11          Scorpion ARMS                               Ex18, 19, 20                   American                                     Direct DNA sequencing or DNA endonuclease-based method (local)   AT liquid biopsy not the same time as biopsy                III or IV              plasma   74%
  *et al.* \[[@r41]\]                                                                                                                                                                                                                                                                                                                                                        

  He *et al.* \[[@r42]\]     2009     18       8        0        1          9           ME-PCR                                      Ex19del, Ex 21 L858R           Asian                                        Direct sequencing                                                BT liquid biopsy, not at the same time.                     Not specified          plasma   94%

  **Study**\                 **TP**   **FP**   **FN**   **TN**   **Test**   **Genes**   **Ethnicity**                               **Test of Biopsy**             **Time Point of Biopsy and Liquid Biopsy**   **Stage**                                                        **Plasma/**\                                                **CR**                          
  **Year**\                                                                                                                                                                                                                                                                      **Serum**                                                                                   
  **Number**                                                                                                                                                                                                                                                                                                                                                                 

  Brevet\                    2011     31       7        2        11         11          Mass spectrometry genotyping assaya         Ex19 del et Ex21 L858R         American                                     PCR-RFLP                                                         BT liquid biopsy not always at the same time.               III or IV              plasma   58%
  *et al.* \[[@r29]\]                                                                                                                                                                                                                                                                                                                                                        

  Jiang\                     2011     58       14       0        4          40          ME-PCR                                      Ex19, 21                       Asian                                        Not specified                                                    BT the same time                                            IIIb, IV               serum    93%
  *et al.* \[[@r43]\]                                                                                                                                                                                                                                                                                                                                                        

  Sriram\                    2011     64       3        0        3          58          ME-PCR and HRM                              EGFR: Ex19 et 21               European                                     ME-PCR et HRM                                                    THE SAME TIME                                               Not specified          serum    95%
  *et al.* \[[@r44]\]                                                                                                                                                                                                                                                                                                                                                        

  Xu *et al.* \[[@r14]\]     2012     34       4        4        4          23          ARMS                                        EGFR 19 del                    Asian                                        ARMS                                                             Liquid AT and tissue BT                                     IIIb a IV              Plasma   79%

  Xu *et al.* \[[@r14]\]     2012     34       4        0        4          26          ARMS                                        EGFR L8585R                    Asian                                        ARMS                                                             Liquid AT and tissue BT                                     IIIb a IV              Plasma   88%

  Xu *et al.* \[[@r14]\]     2012     34       0        1        7          26          DHPLC                                       EGFR 19 del                    Asian                                        ARMS                                                             Liquid AT and tissue BT                                     IIIb a IV              Plasma   76%

  Xu *et al.* \[[@r14]\]     2012     34       2        2        6          24          DHPLC                                       EGFR L8585R                    Asian                                        ARMS                                                             Liquid AT and tissue BT                                     IIIb a IV              Plasma   76%

  Xu *et al.* \[[@r14]\]     2012     34       2        5        5          22          ME-liquidchip                               EGFR 19 del                    Asian                                        ARMS                                                             Liquid AT and tissue BT                                     IIIb a IV              Plasma   70%

  Xu *et al.* \[[@r14]\]     2012     34       2        1        6          25          ME-liquidchip                               EGFR L8585R                    Asian                                        ARMS                                                             Liquid AT and tissue BT                                     IIIb a IV              Plasma   79%

  Kim\                       2013     57       8        3        4          42          PNA-LNA PCR (EGFR), sequencing (KRAS)       EGFR, KRAS                     Asian                                        Direct sequencing                                                The same time BT                                            IIIb, IV               serum    87%
  *et al.* \[[@r20]\]                                                                                                                                                                                                                                                                                                                                                        

  Sequist\                   2015     227      155      23       37         12          NGS (cobas or therascreen)                  EGFR                           American                                     Cobas or therascreen                                             The same time                                               IV after progreesion   plasma   73%
  *et al.* \[[@r25]\]                                                                                                                                                                                                                                                                                                                                                        

  Wu Ya-Lan \[[@r45]\]       2015     24       7        2        10         5           ARMS                                        EGFR\                          Asian                                        ARMS                                                             Yes after treatment                                         IV                     plasma   50%
                                                                                                                                    T 790M                                                                                                                                                                                                                                   

  Mok \[[@r24]\]             2015     238      72       5        24         137         cobas                                       EGFR                           Asian                                        Cobas                                                            Yes before TT                                               IIIb, IV               plasma   87%

  Li \[[@r13]\]              2014     141      27       3        29         62          ARMS                                        EGFR 19 del, L858R, T790M      Asian                                        ARMS                                                             Not specified                                               IIIb, IV               plasma   63%

  Li \[[@r13]\]              2014     108      19       2        29         42          ARMS                                        EGFR 19 del, L858R, T790M      Asian                                        ARMS                                                             Not specified                                               IIIb, IV               serum    56%

  HE \[[@r35]\]              2017     120      80       0        26         14          ddPCR                                       EGFR, Ex19del, L858R, T790M    Asian                                        ddPCR                                                            At the same time, BT                                        Advanced stage         plasma   78%
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CR: concordance rate.

###### 

The pooled sensitivities, specificities and I-square of the sub-groups: NGS technique, ARMS technique, DHPLC technique, same technique in tissue and liquid plasma, screening of Ex19 deletion and L858R mutation, screening of Exons 18, 19, 20.

  ------------------------------------------------------------------------------
  **Sub-groups**                 **Pooled-SEN**           **Pooled-SPE**
  ------------------------------ ------------------------ ----------------------
  NGS                                                     

  Cui S *et al.*\                0.75 \[0.71-0.801\]\     0.82 \[o.77-0.87\]\
  Rachiglio *et al.*\            I2: 56.9%                I2:95.6%
  Santos *et al.*\                                        
  Sequist *et al.*\                                       
  Mok *et al*                                             

  ARMS                                                    

  Goto *et al.*\                 0.509 \[0.461-0.558\]\   0.972 \[0.95-0.98\]\
  Douillard *et al.*\            I2: 83.5%                I2:90.3%
  Liu *et al.*\                                           
  Wang *et al.*\                                          
  Mack *et al.*\                                          
  Kuang *et al.*\                                         
  Xu *et al.*\                                            
  Xu *et al.*\                                            
  Wu *et al.*\                                            
  Li *et al.*\                                            
  Li *et al*                                              

  DHPLC                                                   

  Bai *et al.*\                  0.66 \[0.618-0.709\]\    0.86 \[0.83-0.88\]\
  Que *et al.*\                  I2: 88.1%                I2:40.6%
  Huang *et al.*\                                         
  Xu *et al.*\                                            
  Xu *et al*                                              

  Same technique Tissue/Biopsy                            

  Bai *et al.*\                  0.63 \[0.6-0.65\]\       0.93 \[0.91-0.94\]\
  Cui *et al.*\                  I2:87.3%                 I2:92.4%
  Rachiglio *et al.*\                                     
  Goto *et al.*\                                          
  Douillard *et al.*\                                     
  Huang *et al.*\                                         
  Liu *et al.*\                                           
  Zhao *et al.*\                                          
  Wang *et al.*\                                          
  Jing *et al.*\                                          
  Weber *et al.*\                                         
  Sriram *et al.*\                                        
  Xu *et al.*\                                            
  Xu *et al.*\                                            
  Sequist *et al.*\                                       
  Wu *et al.*\                                            
  Mok *et al.*\                                           
  Li *et al.*\                                            
  Li *et al.*\                                            
  He *et al*                                              

  **Sub-groups**                 **Pooled-SEN**           **Pooled-SPE**

  Ex19 del and L858R mutation                             

  Yung *et al*\                  0.66 \[0.61-0.71\]\      0.94 \[0.92-0.96\]\
  Bai *et al*\                   I2:86.6%                 I2:72%
  Que *et al*\                                            
  Kim *et al*\                                            
  Zhang *et al*\                                          
  Zhu *et al*\                                            
  He *et al*\                                             
  Brevet *et al*\                                         
  Jiang *et al*\                                          
  Sriram *et al*                                          

  Screening exons 18, 19, 20                              

  Kuang *et al*\                 0.63 \[0.57-0.69\]\      0.91 \[0.86-0.95\]\
  Kimura *et al*\                I2:88.1%                 I2:84.4%
  Li *et al*\                                             
  Li *et al*\                                             
  He *et al*                                              
  ------------------------------------------------------------------------------

###### 

Meta-regression analyzing 3 covariates: the test (NGS or not), the ethnicity (Asian or not), the test used in the tissue and the liquid biopsy (the same or not), the use of plasma or serum (serum or not).

  **Covariates**                         **Coefficients**   **P value**
  -------------------------------------- ------------------ -------------
  **Ethnicity**                          0.01               0.98
  **Test**                               -0.49              0.4
  **Test tissue versus liquid biopsy**   0.45               0.37
  **Plasma versus serum**                0.48               0.53
